Therapeutics News

Adalimumab-adbm injection is now available at a low wholesale acquisition cost, Boehringer Ingelheim announced in a company press release.

While the adoption of immunotherapies and targeted systemic therapies for the treatment of melanoma has increased overall survival in patients, it has also significantly increased health care costs, according to a study.

Kenvue Inc. showcased its new topical Tylenol Precise Pain Relieving Cream at PAINWeek Conference 2023 held Sept. 5-8 in Las Vegas, according to a company press release.

In this edition, nearly $1 million in grants to aid diversity, equity, inclusion research; topical halcinonide may benefit patients with psoriasis; Asian patients may experience earlier mycosis fungoides diagnosis and more.

VYNE Therapeutics has announced its second-quarter 2023 financial results as well as business updates for its two novel investigative drugs, according to a press release.

Factors associated with multiple biologic failure in patients with psoriasis may indicate who would benefit from frequent follow-up, according to a study.

Based on the pathogenesis of eosinophilic cellulitis, treatment targeting Janus kinase 1 and 2 should be developed to treat this disease, according to a study.

Compared with the systemic calcineurin inhibitor standard cyclosporine, tacrolimus shows promise for numerous dermatologic conditions, whereas the literature on voclosporin is limited, according to a study.

The photographic exhibition of those with congenital melanocytic nevi had a significant positive impact on participants and attendees, demonstrating options for psychological interventions, according to a study.

Almirall and the Centre for Genomic Regulation have entered into a research collaboration to develop and characterize novel preclinical models for the identification of new nonmelanoma skin cancer treatments, according to a press release.